In addition, we sought to confirm that KXRG capsules reduce HSC activation by suppressing the TGF-β and toll-like receptor (TLR) 4 signaling pathways with the aim of providing more targeted natural medicine for the treatment of NAFLD fibrosis and severe liver diseases. The gene discussed is TGFB1; the disease is metabolic dysfunction-associated steatotic liver disease.